ECSP078001A - Composición farmacéutica que contienen gestágenos y/o estrógenos y 5-metil-(6s)-tetrahidrofolato - Google Patents
Composición farmacéutica que contienen gestágenos y/o estrógenos y 5-metil-(6s)-tetrahidrofolatoInfo
- Publication number
- ECSP078001A ECSP078001A EC2007008001A ECSP078001A ECSP078001A EC SP078001 A ECSP078001 A EC SP078001A EC 2007008001 A EC2007008001 A EC 2007008001A EC SP078001 A ECSP078001 A EC SP078001A EC SP078001 A ECSP078001 A EC SP078001A
- Authority
- EC
- Ecuador
- Prior art keywords
- methyl
- folate
- estrogens
- pharmaceutical composition
- composition containing
- Prior art date
Links
- 239000000262 estrogen Substances 0.000 title abstract 2
- 229940011871 estrogen Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010016880 Folate deficiency Diseases 0.000 abstract 3
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 abstract 2
- 206010010356 Congenital anomaly Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000036244 malformation Effects 0.000 abstract 2
- 206010062334 Congenital genitourinary abnormality Diseases 0.000 abstract 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000002425 cardiocirculatory effect Effects 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 230000002254 contraceptive effect Effects 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 abstract 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 abstract 1
- 229960004845 drospirenone Drugs 0.000 abstract 1
- 229960002568 ethinylestradiol Drugs 0.000 abstract 1
- 229940014144 folate Drugs 0.000 abstract 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 210000001847 jaw Anatomy 0.000 abstract 1
- 210000000088 lip Anatomy 0.000 abstract 1
- 210000001161 mammalian embryo Anatomy 0.000 abstract 1
- 230000000873 masking effect Effects 0.000 abstract 1
- 201000010193 neural tube defect Diseases 0.000 abstract 1
- 229940127234 oral contraceptive Drugs 0.000 abstract 1
- 239000003539 oral contraceptive agent Substances 0.000 abstract 1
- 210000003254 palate Anatomy 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 208000035581 susceptibility to neural tube defects Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000002861 ventricular Effects 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica que contiene gestágenos, preferiblemente drospirenona, estrógenos, preferiblemente etinilestradiol y 5-metil-(6S)-tetrahidrofolato, que puede ser usada como anticonceptivo oral y también previene enfermedades provocadas por carencias de folato de las consumidoras, especialmente enfermedades cardio-circulatorias y después de la concepción del embrión, malformaciones congénitas por carencias de folato, como por ejemplo, defectos del tubo neural, defectos de las válvulas ventriculares, malformaciones urogenitales y hendiduras de labios, mandíbula y paladar, sin enmascarar los síntomas de una carencia de vitamina B12, y en el caso de existir un polimorfismo homo o heterocigota de la metilentetrahidrofolatoreductasa, al mismo tiempo favorece la utilización ilimitada del componente de folato de 5-metil-(6S)-tetrahidrofolato por el organismo, y con ello su actividad biológica, para evitar las malformaciones congénitas provocadas por carencias de folato mencionadas previamente. Además, se mantiene un efecto protector prolongado después de interrumpir el uso del anticonceptivo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005023301A DE102005023301B4 (de) | 2005-05-13 | 2005-05-13 | Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat |
| DE102006016285A DE102006016285A1 (de) | 2006-04-03 | 2006-04-03 | Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP078001A true ECSP078001A (es) | 2008-01-23 |
Family
ID=37396913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2007008001A ECSP078001A (es) | 2005-05-13 | 2007-12-11 | Composición farmacéutica que contienen gestágenos y/o estrógenos y 5-metil-(6s)-tetrahidrofolato |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US20080160004A1 (es) |
| EP (3) | EP2298307A1 (es) |
| JP (2) | JP2008540482A (es) |
| KR (2) | KR20080028369A (es) |
| CN (2) | CN101954083A (es) |
| AR (1) | AR054123A1 (es) |
| AT (2) | ATE429917T1 (es) |
| AU (1) | AU2006245921A1 (es) |
| BR (1) | BRPI0611443B8 (es) |
| CA (1) | CA2608639C (es) |
| CL (2) | CL2009002187A1 (es) |
| CR (1) | CR9531A (es) |
| CY (2) | CY1109261T1 (es) |
| DE (1) | DE502006003617D1 (es) |
| DK (2) | DK1888077T3 (es) |
| DO (1) | DOP2006000110A (es) |
| EA (2) | EA014664B1 (es) |
| EC (1) | ECSP078001A (es) |
| ES (2) | ES2387525T5 (es) |
| GT (1) | GT200600200A (es) |
| HR (1) | HRP20090418T1 (es) |
| IL (1) | IL187340A (es) |
| MA (1) | MA29448B1 (es) |
| MY (1) | MY147362A (es) |
| NO (1) | NO345807B1 (es) |
| PE (1) | PE20061415A1 (es) |
| PL (2) | PL2116249T3 (es) |
| PT (2) | PT2116249E (es) |
| RS (2) | RS50972B (es) |
| SG (1) | SG169973A1 (es) |
| SI (2) | SI2116249T1 (es) |
| SV (1) | SV2008002527A (es) |
| TN (1) | TNSN07418A1 (es) |
| TW (1) | TWI380820B (es) |
| UY (1) | UY29527A1 (es) |
| WO (1) | WO2006120035A2 (es) |
| ZA (2) | ZA200710811B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
| MX2009000256A (es) * | 2006-07-06 | 2009-02-18 | Bayer Schering Pharma Ag | Preparaciones farmaceuticas para la anticoncepcion y para prevenir el riesgo de malformaciones congenitas. |
| US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
| EP1891959A1 (de) * | 2006-08-14 | 2008-02-27 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen |
| CN101489563A (zh) * | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
| UY31010A1 (es) * | 2007-04-05 | 2008-11-28 | Bayer Schering Pharma Ag | Nuevo régimen de drospirenona/17b-estradiol, producto farmacéutico combinado y conjunto de elementos (kit) para su aplicacion |
| US20090170823A1 (en) * | 2007-12-20 | 2009-07-02 | Duramed Pharmaceuticals, Inc. | Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception |
| WO2009112231A2 (en) * | 2008-03-10 | 2009-09-17 | Schuermann Rolf | New drospirenone/17beta-estradil regimen, pharmaceutical combination product and kit for performing this regimen |
| TW200946542A (en) * | 2008-03-10 | 2009-11-16 | Vladimir Hanes | New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |
| KR20130097073A (ko) | 2010-04-15 | 2013-09-02 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 초저-용량의 ｈｒｔ용 고체 경구 투여 형태 |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| EP2617422A1 (en) * | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate |
| EP2781214A1 (en) | 2013-03-22 | 2014-09-24 | Chemo Research, S.L. | Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca) |
| CN107812195B (zh) * | 2014-09-04 | 2021-04-20 | 连云港金康和信药业有限公司 | (6s)‐5‐甲基‐四氢叶酸钙盐的稳定药物组合物 |
| CU24523B1 (es) | 2015-06-18 | 2021-06-08 | Estetra Sprl | Unidad de dosificación orodispersable que contiene un componente estetrol |
| EP3701944B1 (en) | 2015-06-18 | 2021-12-08 | Estetra SRL | Orodispersible dosage unit containing an estetrol component |
| LT3310345T (lt) | 2015-06-18 | 2021-06-25 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| CN106336444A (zh) * | 2016-08-23 | 2017-01-18 | 国家卫生计生委科学技术研究所 | 一种新晶型炔雌醇 |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| EP3781171B1 (en) | 2018-04-19 | 2022-02-09 | Estetra SRL | Compounds and their uses for alleviating menopause-associated symptoms |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK174724B1 (da) * | 1986-07-15 | 2003-10-06 | Wyeth Corp | Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet |
| ZA939565B (en) * | 1993-12-21 | 1994-08-11 | Applied Analytical Ind Inc | Method for preparing low dose pharmaceutical products. |
| US6083528A (en) * | 1995-09-28 | 2000-07-04 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
| JPH11513989A (ja) * | 1995-10-27 | 1999-11-30 | メルク エンド カンパニー インコーポレーテッド | 成長ホルモン分泌促進薬の湿式造粒製剤 |
| ATE262799T1 (de) | 1996-01-31 | 2004-04-15 | Univ South Alabama | Lebensmittel und vitamin herstellungen mit natürlichem isomeren von reduzierten folaten |
| CH693255A5 (de) * | 1997-06-13 | 2003-05-15 | Eprova Ag | Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels. |
| US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
| UA68365C2 (en) * | 1997-11-06 | 2004-08-16 | Wyeth Corp | Peroral contraception by combination of anti-estrogen and progestin |
| CA2329005C (en) * | 1998-04-17 | 2006-01-03 | Ortho-Mcneil Pharmaceutical, Inc. | Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| US7014865B1 (en) | 1998-10-19 | 2006-03-21 | Merck Patent Gmbh | Natural formulation for the treatment and prevention of depression, containing St. John's Wort and derivatives of dihydro- and tetrahydrofolic acid |
| WO2000023089A1 (en) * | 1998-10-19 | 2000-04-27 | Merck Patent Gmbh | Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid |
| CH693905A5 (de) | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
| HU225779B1 (en) | 1999-07-28 | 2007-08-28 | Chinoin Gyogyszer Es Vegyeszet | Pharmaceutical composition containing paracetamol and drotaverine and process for producing it |
| US6787531B1 (en) | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
| DK1380301T3 (da) | 1999-08-31 | 2009-04-20 | Bayer Schering Pharma Ag | Farmaceutisk sammensætning af ethinylestradiol og drospirenon til anvendelse som svangerskabsforebyggende middel |
| US6479545B1 (en) | 1999-09-30 | 2002-11-12 | Drugtech Corporation | Formulation for menopausal women |
| UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| DE10022510A1 (de) | 2000-05-10 | 2001-11-15 | Basf Ag | Zusammensetzungen enthaltend Folsäure und reduziertes Folat |
| JP2004538262A (ja) * | 2000-12-14 | 2004-12-24 | タフツ ユニバーシティー | 関節炎状態を治療するための化合物および方法 |
| US20030045510A1 (en) * | 2000-12-15 | 2003-03-06 | Schloss Caroline Maxine | Estrogen-plus |
| EP1216713A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
| US20060034954A1 (en) * | 2001-02-02 | 2006-02-16 | Bland Jeffrey S | Medical composition for balancing bodily processes |
| US20040220118A1 (en) * | 2001-02-02 | 2004-11-04 | Bland Jeffrey S. | Medical composition for balancing bodily processes |
| JP5037779B2 (ja) * | 2002-02-21 | 2012-10-03 | バイエル ファーマ アクチエンゲゼルシャフト | １又は複数のステロイド、１又は複数のテトラヒドロ葉酸成分およびビタミンｂ１２を含む医薬組成物 |
| UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
-
2006
- 2006-05-11 UY UY29527A patent/UY29527A1/es not_active Application Discontinuation
- 2006-05-12 DO DO2006000110A patent/DOP2006000110A/es unknown
- 2006-05-12 AR ARP060101915A patent/AR054123A1/es not_active Application Discontinuation
- 2006-05-12 TW TW095116905A patent/TWI380820B/zh not_active IP Right Cessation
- 2006-05-12 PE PE2006000504A patent/PE20061415A1/es active IP Right Grant
- 2006-05-12 SV SV2006002527A patent/SV2008002527A/es active IP Right Grant
- 2006-05-12 GT GT200600200A patent/GT200600200A/es unknown
- 2006-05-15 DE DE502006003617T patent/DE502006003617D1/de not_active Expired - Lifetime
- 2006-05-15 PT PT09075120T patent/PT2116249E/pt unknown
- 2006-05-15 JP JP2008510518A patent/JP2008540482A/ja not_active Withdrawn
- 2006-05-15 EP EP10185658A patent/EP2298307A1/de not_active Withdrawn
- 2006-05-15 CN CN2010101564516A patent/CN101954083A/zh active Pending
- 2006-05-15 BR BRPI0611443A patent/BRPI0611443B8/pt active IP Right Grant
- 2006-05-15 AU AU2006245921A patent/AU2006245921A1/en not_active Abandoned
- 2006-05-15 DK DK06753787T patent/DK1888077T3/da active
- 2006-05-15 SI SI200631375T patent/SI2116249T1/sl unknown
- 2006-05-15 EP EP09075120.7A patent/EP2116249B2/de not_active Expired - Lifetime
- 2006-05-15 NO NO20076408A patent/NO345807B1/no unknown
- 2006-05-15 EP EP06753787A patent/EP1888077B1/de not_active Expired - Lifetime
- 2006-05-15 KR KR1020077029090A patent/KR20080028369A/ko not_active Ceased
- 2006-05-15 PT PT06753787T patent/PT1888077E/pt unknown
- 2006-05-15 CN CN2006800164109A patent/CN101198332B/zh not_active Expired - Lifetime
- 2006-05-15 MY MYPI20062228A patent/MY147362A/en unknown
- 2006-05-15 RS RSP-2009/0327A patent/RS50972B/sr unknown
- 2006-05-15 SI SI200630360T patent/SI1888077T1/sl unknown
- 2006-05-15 ES ES09075120T patent/ES2387525T5/es not_active Expired - Lifetime
- 2006-05-15 AT AT06753787T patent/ATE429917T1/de active
- 2006-05-15 ES ES06753787T patent/ES2325600T3/es not_active Expired - Lifetime
- 2006-05-15 KR KR1020147010192A patent/KR101598735B1/ko not_active Expired - Lifetime
- 2006-05-15 EA EA200702349A patent/EA014664B1/ru active Protection Beyond IP Right Term
- 2006-05-15 DK DK09075120.7T patent/DK2116249T3/da active
- 2006-05-15 PL PL09075120T patent/PL2116249T3/pl unknown
- 2006-05-15 EA EA200901393A patent/EA028530B1/ru not_active IP Right Cessation
- 2006-05-15 WO PCT/EP2006/004858 patent/WO2006120035A2/de not_active Ceased
- 2006-05-15 PL PL06753787T patent/PL1888077T3/pl unknown
- 2006-05-15 RS RS20120325A patent/RS52651B/sr unknown
- 2006-05-15 AT AT09075120T patent/ATE555791T1/de active
- 2006-05-15 SG SG201007499-5A patent/SG169973A1/en unknown
- 2006-05-15 HR HR20090418T patent/HRP20090418T1/xx unknown
- 2006-05-15 CA CA2608639A patent/CA2608639C/en not_active Expired - Fee Related
-
2007
- 2007-11-12 US US11/938,688 patent/US20080160004A1/en not_active Abandoned
- 2007-11-12 TN TNP2007000418A patent/TNSN07418A1/en unknown
- 2007-11-13 MA MA30367A patent/MA29448B1/fr unknown
- 2007-11-13 IL IL187340A patent/IL187340A/en active IP Right Grant
- 2007-11-16 CR CR9531A patent/CR9531A/es not_active Application Discontinuation
- 2007-12-11 EC EC2007008001A patent/ECSP078001A/es unknown
- 2007-12-12 ZA ZA2007/10811A patent/ZA200710811B/en unknown
-
2009
- 2009-07-28 CY CY20091100804T patent/CY1109261T1/el unknown
- 2009-12-14 ZA ZA2009/08894A patent/ZA200908894B/en unknown
- 2009-12-18 CL CL2009002187A patent/CL2009002187A1/es unknown
-
2010
- 2010-09-21 CL CL2010000989A patent/CL2010000989A1/es unknown
-
2012
- 2012-08-02 CY CY20121100689T patent/CY1114403T1/el unknown
-
2013
- 2013-02-18 JP JP2013029277A patent/JP5883810B2/ja not_active Expired - Lifetime
-
2015
- 2015-12-10 US US14/965,173 patent/US10463666B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2006000110A (es) | Composición farmaceútica que contiene gestágenos y/o estrógenos y 5-metil-(6s)-tetrahidrofolato | |
| AR106561A2 (es) | Composición farmacéutica que contiene un ácido tetrahidrofólico | |
| DOP2009000135A (es) | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituídos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis | |
| HN2005000795A (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2 | |
| CL2008001721A1 (es) | Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales. | |
| HN2011003011A (es) | Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas | |
| UY37971A (es) | Derivados de indol macrocíclicos sustituidos | |
| BR112012013164A2 (pt) | composições farmacêuticas para o estímulo de células-tronco | |
| DOP2022000031A (es) | [1,2,4]triazolo[1,5-c]quinazolin-5-aminas | |
| PE20211588A1 (es) | Compuestos y sus usos para aliviar sintomas asociados a la menopausia | |
| ECSP055575A (es) | Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel. | |
| UY30461A1 (es) | Composicion farmacéutica para la anticoncepcion y para reducir el riesgo de malformaciones congénitas. | |
| ECSP088472A (es) | Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento | |
| CL2008002060A1 (es) | Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras. | |
| CU20070252A7 (es) | Composición farmacéutica que contiene drospirenona, etinilestradiol y la sal de calcio del ácido 5-metil-(6s)-tetrahidrofólico | |
| CL2015003014A1 (es) | Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas. | |
| JOP20100287B1 (ar) | مركب دوائي يشتمل على بروجستينات واستروجينات، احدهما او كلاهما، و5 - مثيل - (6s)- رابع هايدروفولات | |
| GT200600272A (es) | Moduladores no esteroides de receptores de progesterona | |
| CL2008003920A1 (es) | Compuesto derivado de gama-lactona del esteroide del acido 15,16-metilen-17-hidroxi-19-nor-21-carboxilico, dispositivo intrauterino que lo contiene y su uso para la contracepcion oral y para trastornos pre, peri y postmenopausicos. | |
| GT200600271A (es) | Moduladores no esterides de receptores de progesterona | |
| DOP2007000117A (es) | Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas | |
| CU20060219A7 (es) | Formulaciones con liberación controlada de principio activo que contiene vardenafilo |